616 / 1224
Dose in relation to volume: OARs
Adebahr S et al. BJR 2015, EORTC Lungtech trial
* Following Mangona, IJROBP 91(1) p124-132 2015, William Beaumont Hospital
OAR
αβ
in Gy
D
max
in Gy
EqD2
in Gy
Acceptable
variation
in Gy
Unacceptable
variation
in Gy
Unacceptable
variation
EqD2 in Gy
Trachea/ MainBronchus
3
8*5.5= 44
74.8
<8*5.81=46.68
≥8*5.81=46.68
≥81.9
Heart
§
3
GreatVessels
§
3
Esophagus
3
8*5 = 40
64
<8*5.44=43.52
≥8*5.44=43.52
≥73.6
SpinalCord
&
2
8*4= 32
48
>8*4=32
≥48
BrachialPlexus
&
3
8*4.75=38
58.9
<8*5.17=41.36
≥8*5.17=41.36
≥ 67.7
External-PTV
&
3
8*7.5= 60
126
<8*7.785=62.28
≥8*7.785=62.28
≥134.2
Lungs-CTV
§
3
ChestWall
§
3
&
for <0.5 cc
§ no restrictions are provided but recording of DVH data for toxicity evaluation is required
EORTC 22113-0813-LungTech RTQA Guidelines
l
t l
i ti
i
t le
i ti
i
.
.
.
.
.
t
*
8*5.5= 44
74.8
<8*6=48
≥8*6=48
≥86.4
t e sels
*
8*5.5= 44
74.8
<8*6=48
≥8*6=48
≥86.4
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
-
*
V20Gy<6%
V20<10%
V20Gy≥10%
l
§
8*8.25=66
148.5
≥8*9=72
≥172.8
it
l ti i r ir
Catharina Cancer Centre guidelines